Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 11;74(3):472-478.
doi: 10.1093/cid/ciab438.

The Effectiveness of the Two-Dose BNT162b2 Vaccine: Analysis of Real-World Data

Gabriel Chodick  1   2 , Lilac Tene  1 , Ran S Rotem  1   3 , Tal Patalon  1 , Sivan Gazit  1 , Amir Ben-Tov  1   2 , Clara Weil  1 , Inbal Goldshtein  1   2 , Gilad Twig  2   4   5   6 , Dani Cohen  2 , Khitam Muhsen  2
Affiliations

The Effectiveness of the Two-Dose BNT162b2 Vaccine: Analysis of Real-World Data

Gabriel Chodick et al. Clin Infect Dis. .

Abstract

Background: Coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccines were shown to be highly efficacious in preventing the disease in randomized controlled trials; nonetheless, evidence on the real-world effectiveness of this vaccine is limited. Study objective was to evaluate the effectiveness of BNT162b2 vaccine in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19-related hospitalization and mortality.

Methods: This historical cohort study included members of a large health provider in Israel that were vaccinated with at least 1 dose of BNT162b2. The primary outcome was incidence rate of a SARS-CoV-2 infection confirmed with real-time polymerase chain reaction (rt-PCR), between 7 and 27 days after second dose (protection-period), as compared to days 1-7 after the first dose, where no protection by the vaccine is assumed (reference-period).

Results: Data of 1 178 597 individuals vaccinated with BNT162b2 were analyzed (mean age 47.7 years [SD = 18.1], 48.4% males) of whom 872 454 (74.0%) reached the protection period. Overall, 4514 infections occurred during the reference period compared to 728 during the protection period, yielding a weighted mean daily incidence of 54.8 per 100 000 (95% confidence interval [CI]: 26.1-115.0 per 100 000) and 5.4 per 100 000 (95% CI: 3.5-8.4 per 100 000), respectively. The vaccine effectiveness in preventing infection was 90% (95% CI: 79%-95%) and 94% (95% CI: 88%-97%) against COVID-19. Among immunosuppressed patients, vaccine effectiveness against infection was 71% (95% CI: 37%-87%). The adjusted hazard ratios for hospitalization in those infected were 0.82 (95% CI: .36-1.88), 0.45 (95% CI: .23-.90), and 0.56 (95% CI: .36-.89) in the age groups 16-44, 45-64. and ≥75 years, respectively.

Conclusions: The effectiveness of the BNT162b2 vaccine is comparable to the one reported in the phase III clinical trial.

Keywords: BNT162b2; COVID-19; effectiveness; real-world data; vaccine.

PubMed Disclaimer